Malignant Mesothelioma – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026
- Published Date : September 7, 2026
- Updated On : November 3, 2026
- Pages : 53
Malignant Mesothelioma Emerging Therapy and TPP Insights
Thelansis’s “Malignant Mesothelioma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Malignant Mesothelioma Overview
Malignant mesothelioma is an aggressive cancer of mesothelial linings, most often the pleura and less often the peritoneum. Asbestos exposure is the main risk factor; BAP1, NF2 and CDKN2A alterations are common. Pleural disease may cause breathlessness, chest pain and effusion; peritoneal disease can cause abdominal pain, distension and ascites. Biopsy establishes diagnosis and histologic subtype. Treatment depends on site, stage, histology and fitness. Unresectable pleural disease may be treated with nivolumab plus ipilimumab or pembrolizumab with platinum and pemetrexed. Selected peritoneal cases may undergo cytoreductive surgery with HIPEC; systemic treatment is tailored to histology and risk. Research includes mesothelin-directed CAR T cells, antibody-drug conjugates, arginine depletion and therapies targeting BAP1- or MTAP-related vulnerabilities. These remain investigational; durable disease control remains difficult. Care should be coordinated by a specialist multidisciplinary team.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and enriched by insights from interviews with leading KOLs
*Survey is customized based on client requirements
Deliverables format:
- PowerPoint presentation
- MS Excel
Key business questions answered:
- Detailed emerging competitive landscape
- Pipeline analysis
- Target patients for emerging therapies
- Key companies
- Key mechanism of actions
- Launch date estimates, etc.
- Clinical trial landscape analysis
- Target patient segments
- Trial endpoints
- Trial design
- Recruitment criteria, etc.
- Unmet Needs and Opportunities
- Performance of key current therapies
- Top areas of unmet needs
- Opportunity sizing for key unmet needs
- Target Product Profiles
- Attributes and levels
- Physician likelihood of prescribing
- Expected patient shares
- KOL insights on key emerging therapies
- Level of awareness
- Expected use / line of therapy
- Extent to fulfil key unmet needs
- KOL quotes
Malignant Mesothelioma Emerging Therapy and TPP Insights
Thelansis’s “Malignant Mesothelioma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Malignant Mesothelioma Overview
Malignant mesothelioma is an aggressive cancer of mesothelial linings, most often the pleura and less often the peritoneum. Asbestos exposure is the main risk factor; BAP1, NF2 and CDKN2A alterations are common. Pleural disease may cause breathlessness, chest pain and effusion; peritoneal disease can cause abdominal pain, distension and ascites. Biopsy establishes diagnosis and histologic subtype. Treatment depends on site, stage, histology and fitness. Unresectable pleural disease may be treated with nivolumab plus ipilimumab or pembrolizumab with platinum and pemetrexed. Selected peritoneal cases may undergo cytoreductive surgery with HIPEC; systemic treatment is tailored to histology and risk. Research includes mesothelin-directed CAR T cells, antibody-drug conjugates, arginine depletion and therapies targeting BAP1- or MTAP-related vulnerabilities. These remain investigational; durable disease control remains difficult. Care should be coordinated by a specialist multidisciplinary team.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and enriched by insights from interviews with leading KOLs
*Survey is customized based on client requirements
Deliverables format:
- PowerPoint presentation
- MS Excel
Key business questions answered:
- Detailed emerging competitive landscape
- Pipeline analysis
- Target patients for emerging therapies
- Key companies
- Key mechanism of actions
- Launch date estimates, etc.
- Clinical trial landscape analysis
- Target patient segments
- Trial endpoints
- Trial design
- Recruitment criteria, etc.
- Unmet Needs and Opportunities
- Performance of key current therapies
- Top areas of unmet needs
- Opportunity sizing for key unmet needs
- Target Product Profiles
- Attributes and levels
- Physician likelihood of prescribing
- Expected patient shares
- KOL insights on key emerging therapies
- Level of awareness
- Expected use / line of therapy
- Extent to fulfil key unmet needs
- KOL quotes
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.
2. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key emerging therapies – profiles and KOL insights
3. Product Attribute Analysis
- Key takeaways
- Scientific attributes
- Commercial attributes
- Product positioning
4. Primary Market Research
- Current treatment landscape
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Current challenges
- Unmet needs
- Emerging therapies
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Unmet needs and KOL expectations
5. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.
2. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key emerging therapies – profiles and KOL insights
3. Product Attribute Analysis
- Key takeaways
- Scientific attributes
- Commercial attributes
- Product positioning
4. Primary Market Research
- Current treatment landscape
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Current challenges
- Unmet needs
- Emerging therapies
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Unmet needs and KOL expectations
5. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
